Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HRH1 | P35367 | 3/20 | 0.38 |
| ▸ | KIF11 | P52732 | 2/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17261331 | 0.98 | MAOA (0.42) | MAOAHTR2AHRH1KIF11LOXL2 | |
| SCHEMBL31561298 | 0.85 | HTR2A (0.37) | MAOAHTR2AHRH1KIF11LOXL2 | |
| Hydrochloric Acid SCHEMBL3668039 | 0.83 | HTR2A (0.36) | MAOAHTR2AHRH1KIF11LOXL2 | |
| SCHEMBL20921242 | 0.79 | CYP3A4 (0.38) | — | |
| SCHEMBL1314975 | 0.79 | CYP3A4 (0.38) | — | |
| SCHEMBL10915478 | 0.79 | — | — | |
| SCHEMBL7333201 | 0.79 | — | — | |
| SCHEMBL10835174 | 0.79 | TDP1 (0.33) | — | |
| SCHEMBL6002849 | 0.79 | CES2 (0.39) | SMN1; SMN2SIGMAR1 | |
| SCHEMBL12040835 | 0.78 | CES2 (0.41) | SMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143009-B1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2019-09-18 | — | — | EP | disclosed |
| US-20170182009-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-29 | — | — | US | disclosed |
| US-20130142739-A1 | PROCESS FOR THE SYNTHESIS OF ISOTHIOCYANATES AND DERIVATIVES THEREOF AND USES OF SAME | AURIGA INTERNATIONAL (BE) | 2013-06-06 | — | — | US | disclosed |
| EP-2595953-A1 | PROCESS FOR THE SYNTHESIS OF ISOTHIOCYANATES AND DERIVATIVES THEREOF AND USES OF SAME | Auriga International (BE) | 2013-05-29 | — | — | EP | disclosed |
| CN-103025710-A | Process for the synthesis of isothiocyanates and derivatives thereof and uses of same | AURIGA INTERNAT | 2013-04-03 | — | — | CN | disclosed |
| WO-2012010644-A1 | PROCESS FOR THE SYNTHESIS OF ISOTHIOCYANATES AND DERIVATIVES THEREOF AND USES OF SAME | AURIGA INTERNATIONAL (BE) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142739-A1 | PROCESS FOR THE SYNTHESIS OF ISOTHIOCYANATES AND DERIVATIVES THEREOF AND USES OF SAME | TST, CBS, SRM | MAOA 4435/4885HTR2A 2762/4885HRH1 2387/4885 |
| US-20170182009-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | ASAH1, ASAH2, ACER2 | MAOA 698/4885HTR2A 4183/4885HRH1 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.